Maximus, Inc. (MMS) is a Tysons, Virginia-based provider of technology-enabled government services, administering health and human services programs, eligibility and enrollment support, clinical assessments, and defense-related technology work for U.S. federal, state, and international agencies. The stock fell 4.17% on Thursday, trading at $62.54 against a prior close of $65.26, a decline of $2.72. The move followed the company's fiscal fourth-quarter and full-year results for the period ended September 30, which showed revenue and adjusted earnings slightly below consensus and a fiscal 2027 profit outlook whose midpoint sits marginally under analyst estimates. Direction was confirmed lower from the opening bell, with shares gapping down to $63.50 and touching $61.15 intraday.
Maximus reported fourth-quarter revenue of $1.30 billion, down 1.3% from $1.32 billion a year earlier and just shy of consensus. Adjusted earnings of $2.11 per share missed the $2.31 consensus, while GAAP diluted earnings rose to $1.83 from $1.32. The shortfall was modest, and adjusted EPS still exceeded the company's own implied fourth-quarter guidance of about $1.91, but investors focused on the second consecutive quarter of revenue pressure.
Segment trends were mixed. U.S. Federal Services revenue slipped to $2.99 billion for the year from $3.07 billion, a comparison distorted by roughly $100 million of elevated disaster-support and clinical volume in the prior year, though operating margin expanded to 18.1% from 15.3%. U.S. Services revenue fell to $1.68 billion and included a $6.9 million non-cash software impairment. Outside the U.S. posted $557 million of revenue and a small operating loss, the weakest part of the portfolio.
Management guided fiscal 2027 to revenue of $5.45 billion to $5.65 billion, comfortably above the roughly $5.23 billion consensus, and includes about ten months of contribution from Agile Defense, whose acquisition closed November 18. The catch was profitability: adjusted EPS of $7.50 to $8.00, a midpoint of $7.75, versus approximately $8.01 expected, with adjusted EBITDA margin guided to about 12.8%.
The bridge explains much of the caution. Fiscal 2026 included an estimated $75 million of revenue and $1.05 per share of adjusted profit tied to VA Medical Disability Exam incentives that the company does not assume repeats. Stripping that out, the midpoint implies roughly 8% comparable growth, but the headline number still reads as a guide-down against published estimates.
The most uncomfortable item was cash. Full-year operating cash flow of $112 million and free cash flow of $69 million came in dramatically below the $425 million to $475 million guidance, driven by customer collection timing; more than $330 million was collected after year-end through November 13. Management guided fiscal 2027 free cash flow of $700 million to $800 million, but the gap between earnings and cash remains a credibility question for investors.
Separately, the VA released a formal solicitation for the Medical Disability Exam program with bids due in mid-December. The new contract is structured as a five-year vehicle rather than the ten years previously assumed, beginning July 1, 2027, which trimmed roughly $5.6 billion from the reported $44.8 billion pipeline. A trailing twelve-month book-to-bill of 0.5 times reinforced concerns about awards timing.
The selling was company-specific rather than sector-wide. Government services peers moved only modestly: BAH slipped 1.11%, GIB lost 1.52%, CACI eased 0.39%, and LDOS was roughly flat. The industrial sector benchmark shed about 1.0% and the broad market was down about 0.3%, a mild risk-off backdrop that amplified rather than caused the decline.
Technically, shares opened below their 20-day average near $64.89, broke under the $63 area that had held in mid-November, and printed a session low of $61.15 before stabilizing. Volume tracked near normal early-session levels rather than showing capitulation-style selling, consistent with orderly de-risking after a 33% rally from the late-September low near $52 to the November 5 high of $69.22. The stock remains roughly 37% below its 52-week high of $100.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Maximus earns 40 out of 100.
The verified news was moderate rather than transformative: a slight revenue miss, adjusted EPS below consensus, a fiscal 2027 profit midpoint a few percent under estimates, and a large free cash flow shortfall, partly offset by above-consensus revenue guidance and margin expansion. The price reaction was roughly 2.7 times the stock's average absolute daily move of about 1.5% over the past 60 sessions, but declines of 4.2% or more have occurred six times in that window, so the move is not statistically rare for this name. Moderate news plus a familiar-sized move produces a mid-range score.
Attention now shifts to execution on the fiscal 2027 plan. The December 11 deadline for states to opt into the CMS option that can suppress Medicaid work-requirement denials and disenrollments for six months is a key policy variable for the U.S. Services recovery, as is the mid-December VA MDE bid submission and the timing of an award. Investors will also watch whether free cash flow normalizes as receivables convert and how quickly Agile Defense contributes to federal revenue.
Analysts currently model fiscal 2027 EPS near $8.01, above the company's midpoint, leaving room for estimate revisions in the coming weeks. The next quarterly report, for fiscal first quarter 2027, is expected in February. Principal risks include federal procurement delays, continued weakness in the Outside the U.S. segment, margin pressure from the absence of VA incentive payments, and the heavy dependence of the growth story on state-level policy implementation. The quarterly dividend of $0.33 per share is payable November 30.
Tickeron's Trending AI Robots page offers a curated view of the platform's strongest automated strategies under current market conditions. Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only those posting the best results right now are featured in this section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup shifts as market conditions change. Traders seeking systematic approaches to volatile single-stock moves may find it a useful starting point for their own research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The 10-day moving average for MMS crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.
Following a +1.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where MMS advanced for three days, in 157 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.
The Aroon Indicator entered an Uptrend today. In 99 of 186 cases where MMS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 53%.
The 10-day RSI Indicator for MMS moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 15 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 65%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MMS as a result. In 48 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
The Moving Average Convergence Divergence Histogram (MACD) for MMS turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 21 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 48%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
MMS broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.970) is normal, around the industry mean (5.887). P/E Ratio (9.604) is within average values for comparable stocks, (33.618). Projected Growth (PEG Ratio) (0.380) is also within normal values, averaging (1.946). Dividend Yield (0.020) settles around the average of (0.025) among similar stocks. P/S Ratio (0.604) is also within normal values, averaging (9.907).
The Tickeron SMR rating for this company is 45 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. MMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 83 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of business process services to government health and human services agencies
Industry OfficeEquipmentSupplies